Diagnostic efficacy and safety of 99mTc-labeled monoclonal antibody Ior c5 in patients with colorectal and anal carcinomas: Final report clinical trial phase I/II

Cancer Biology and Therapy

Volumn 6, Issue 1, 2007, Pages 22-29

  Ramos Suzarte, Mayra ^a   Pintado, Alejandro P ^b   Mesa, Nelson Rodríguez ^c   Oliva, Juan P ^d   Iznaga Escobar, Normando ^a   Aroche, Leonel T ^b   Pimentel, Gilmara ^d   González, Joaquín ^d   Cordero, Maria ^c   Rodríguez, Obaya T ^a   Crombet, Ramos T ^e   Pérez, Rodríguez R ^e  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Centre for Clinical Research   (Cuba)

^c Medical Surgical Research Center   (Cuba)

^d INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^e Center of Molecular Immunology ^*

Author keywords

Anal; Cancer; Colorectal; IOR C2 antigen; Ior c5 AcM; Patients; Radioimmunoscintigraphy

Indexed keywords

MONOCLONAL ANTIBODY TC 99M;

ABSENCE OF SIDE EFFECTS; ADULT; AGE DISTRIBUTION; AGED; ANUS CARCINOMA; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 33847106462     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.1.3552     Document Type: Article

References (20)

1. FDA Approves first angiogenesis inhibitor to treat colorectal cancer. http://www.fda.gov/bbs/topics/NEWS/2004/NEW01027.html.
2. Estadísticas de Salud en Cuba. Anuario Estad́stico de Salud: Ministerio de Salud Pública de Cuba. 2005, (http://bvs.sld.cu/cgibin/ wxis/anuario/?IsisScript=anuario/iah.xis&tag5001=mostrar∧m1160& tag5009=STANDARD&tag5008=10&tag5007=Y&tag5003=anuario&tag5021= e&tag5022=2004&tag5023=1160).
3. Vázquez AM, Tormo BR, Alfonso M, et al. Characterization of ior C5 colorectal tumor associated antigen. Inmunología Española 1995; 14:130-32.
4. Vázquez AM, Tormo BR, Velandia A, et al. Characterization of Colorectal Antigen ior C2. Hybridoma 1992; 11:245-56.
5. Vázquez AM, Tormo BR, Velandia A, et al. Characterization of the colorectal antigen ior C2. II. The Year in Immunol. Basel, Karger: 1993:7:137-45.
6. Tormo BR, Vazquez AM, Chong A. Colon Cancer Associated Antigen expression on normal and neoplastic human tissues detected by ior C2: A novel monoclonal antibody. Biotecnología Aplicada 1991; 8:206-15.
7. Iznaga-Escobar N, Ramos-Suzarte M, Morales-Morales A, Torres-Arocha L, Rodriguez-Mesa N, Pérez-Rodriguez R. 99mTc labeled murine ior c5 monoclonal antibody in colorectal carcinoma patients: Pharmacokinetics, bio distribution, absorbed radiation doses to normal organs and tissues and tumor localization. Methods Find Exp Clin Pharmacol 2004; 26:687-96.
8. Solano ME, Perera A, Batista JF, et al. Immunoscintigraphic diagnosis of Ovarian Cancer with Tc- 99m labeled MAb ior-c5: First Clinical Results. World J Nucl Med 2003; 2:30-6.
9. Schwarz A, Steinstrasser A. A novel approach to Tc-99m-labeled monoclonal antibodies. J Nucl Med 1987; 28:721.
10. Iznaga -Escobar N, Morales A, Núñez G. Micro method for quantification of SH groups generated after reduction of monoclonal antibodies. Nuc Med Biol 1996; 23:641-4
11. Morales A, Zayas F, Núñez G, Escobar N, Pérez N, Izquierdo JC. Technetium-99m directs radiolabeling of monoclonal antibody ior egf/r3. Nuc Med biol 1998; 25:25-30.
12. Goldenberg DM, Divgi G, Juwei M, Sharkey RM, Burton J, Alavi A. Radioimmunotherapy of B cell lymphatic tumors with a radiodinated, humanized, anti CD 22 monoclonal Antibody, hLL2. European Journal of Nuclear Medicine 1998; 25/8.
13. Oncology Therapy 873:OS-145.RAIT.
14. Ramos-Suzarte M, Rodríguez N, Oliva JP, et al. 99mTc Labeled anti human epidermal growth factor receptor antibody in patients with tumors of epithelial origen: Part III. Clinical Trials Safety and diagnostic Efficacy. J Nuc Med 1999; 40:768-75.
15. Quesada CW, Pimentel GG, Oliva JP, Perez TG, Rebustillo SM. Radiolabeling of a new agent for the study of colorectal tumors. Rev Esp Med Nucl 1998; 17:82-8.
16. Hakomori S. Aberrant Glycosilation in cancer cell membranes as focused of glycolipids: Overview and perspectives. Cancer Res 1985; 45:2405-14.
17. McKensie IFC. Mucins in breast cancer: Recently immunological advances. Cancer Cell 1990; 2:75-8.
18. Schumann D, Chen CJ, Kaplan B, Shively JE. Carcinoembrionic antigen cell adhesion molecule 1 directly associates with cytoskeleton protein actin and tropomyosin. J Biol Chem 2001; 279:47421-33.
19. Levine DS, Haggitt RC. Normal Histology of the colon. Am J Sur Pathol 1989; 13:966-84.
20. Fenger C. Histology of the anal canal. Am J Surg Pathol 1988; 12:41-55.